Breaking the limit of chemical compounds

Phys.org | June 24, 2020

Since the end of the 19th century, transition metal carbonyls have been an important and familiar class of compound in coordination chemistry and organometallic chemistry. In these materials, carbon monoxide molecules (CO) are bound to transition metals as the central atom. In this subject area, the team of Prof. Dr. Ingo Krossing and Wiebke Unkrig of the Institute of Inorganic and Analytical Chemistry at the University of Freiburg has succeeded in synthesizing brand-new transition metal carbonyl complexes—Ta2(CO)12 and M(CO)7+, where the metal atoms M are Niobium (Nb) and Tantalum (Ta). In many aspects, these substances go beyond current compound limits. As a result, they transcend new chemical frontiers that are relevant for practical use as well as basic science. The researchers have published their results in the scientific journal Nature Chemistry.

They have synthesized the dinuclear compound Ta2(CO)12—which is considered the first new, neutral carbonyl complex to be synthesized in the 21st century. What is more, they managed to "bottle" positively charged carbonyl complexes with seven CO ligands by combination with a weakly-coordinating anion as a stable substance. No matter which of the thirty known transition metals were used, until now, complex compounds with more than six CO molecules were not accessible in substance. Evidence for such molecules was observed only in the gas phase.

Spotlight

CleanChain™, an ADEC Innovation, provides a secure, central solution for managing chemical inventory so your staff have the critical performance insights and improvement plans needed to better run your business – and be rewarded for doing so. Monitoring the progress of your chemical management commitments throughout your extended supply chain is a very manual, labor-intensive process. Rather than spending time managing the data and aggregating information from diverse and distributed sources, ADEC Innovations’ CleanChain provides one system for your chemical data across all suppliers.

Spotlight

CleanChain™, an ADEC Innovation, provides a secure, central solution for managing chemical inventory so your staff have the critical performance insights and improvement plans needed to better run your business – and be rewarded for doing so. Monitoring the progress of your chemical management commitments throughout your extended supply chain is a very manual, labor-intensive process. Rather than spending time managing the data and aggregating information from diverse and distributed sources, ADEC Innovations’ CleanChain provides one system for your chemical data across all suppliers.

Related News

CHEMICAL MANAGEMENT

Technip Energies collaborate with Agilyx to accelerate and scale-up the implementation of its polystyrene recycling technology

Technip Energies, Technip Energies | June 04, 2021

PARISandOSLO, Norway,Technip Energies announced today the initiation of an agreement with Agilyx Corporation ("Agilyx"), a wholly owned subsidiary of Agilyx AS (Euronext Growth (Oslo): ("AGLX"), and pioneer in the advanced recycling of post-use plastics. This collaboration aims to accelerate the implementation of Agilyx's technology for the advanced recycling of post-use polystyrene. Under this agreement, Technip Energies will market and license the integrated technologies of Agilyx depolymerization and Technip Energies purification technology, leveraging the expertise, resources, and global presence of respective companies. Both companies bring strong, specialized experience to this offering: Agilyx contributes its deep experience in chemical recycling of post-use plastics, while Technip Energies has extensive experience in scaling-up technology which will increase the plastic recovery. Stan Knez, Chief Technology Officer of Technip Energies, stated,"We are delighted to scale-up this sustainable process to market with Agilyx, providing a reliable circular economy technology for a major plastic used widely throughout the world." Tim Stedman, CEO of Agilyx, said: "We're excited to be working with Technip Energies.This partnership further accelerates the deployment of polystyrene circularity in the market, broadening polystyrene recyclability." Agilyx's proprietary advanced recycling technology converts post-use plastics back into their original chemical components such that they can be used to produce high-quality products that can be recycled indefinitely, without degradation.

Read More

CHEMICAL TECHNOLOGY

NuMat Technologies and Sumitomo Chemical Announce Partnership to Develop Chemical Separation Technologies to Drive Industrial Carbon Neutrality

Sumitomo Chemical Company Limited | August 25, 2021

NuMat Technologies, Incorporated today announced a partnership with Sumitomo Chemical Co., Ltd. to develop sustainable chemical separation technologies that can efficiently and dramatically reduce the carbon emissions and carbon footprint required to produce critical chemicals used in key sectors of the global economy. Traditional chemical separation processes require substantial energy to operate, and significant capital investment. The drive for energy-efficient and cost-effective alternatives is of critical importance to achieve carbon emission reduction objectives outlined in the Paris Climate Agreement. Through this collaboration, both companies will apply their world-class expertise in advanced separation and precision-engineered materials to develop novel solutions that can displace incumbent technologies longer-term, while working towards near-term commercial targets. NuMat is a platform chemistry design company, innovating at the intersection of high-performance computing, data engineering and chemistry to deliver transformational solutions to the chemicals, industrials, electronics and life-science sectors. A pioneer in the field of Programmable Chemistries, including Metal-Organic Frameworks, NuMat takes a precision-medicine approach to chemistry – tailor designing materials to solve big challenges at the smallest possible level. "We're proud to partner with Sumitomo Chemical in unleashing the potential of Programmable Chemistries to address complex sustainability challenges in the chemicals industry," stated Ben Hernandez, Founder and Chief Executive Officer at NuMat Technologies. "Sumitomo Chemical and NuMat are joined by a shared mission to use chemistry in solving the problems that matter, and I’m excited at the innovation opportunities our collaboration can unlock." Sumitomo Chemical, a leading Japanese chemical company, was founded with a mission to drive societal impact and solve environmental challenges through technology. They have been exploring new opportunities to achieve carbon neutrality by 2050. "We are pleased to tackle the emission reduction challenges in the chemical industry with NuMat. This partnership is aligned with our carbon neutral strategy and intentions. We are looking forward to exploring the synergies from working with NuMat, allowing us to accelerate and enhance the discovery, development and delivery of innovative separation solutions that require less energy." said Junpei Tsuji, Associate Officer, General Manager of Research Planning and Coordination Department at Sumitomo Chemical. About NuMat Technologies, Incorporated NuMat is a chemistry design company, innovating at the intersection of high-performance computing, data engineering and chemistry to deliver transformational solutions to the chemicals, industrials, electronics and life-science sectors. A pioneer in field of Programmable Chemistries including Metal-Organic Frameworks ("MOFs), NuMat programs materials to uniquely interact with target molecules at the atomic level, and then integrates these materials into next-generation encapsulation, separation and catalytic solutions. NuMat provides a total solutions platform for product commercialization, pairing world-class material discovery software with application development and manufacturing expertise. About Sumitomo Chemical Company Limited Sumitomo Chemical, was founded in 1913 and is one of Japan's leading chemical companies with global sales of nearly $21 Billion. The company operates worldwide in such diverse business sectors as Petrochemicals & Plastics, Energy & Functional Materials, IT-related Chemicals, Health & Crop Sciences, and Pharmaceuticals. The Sumitomo Chemical Group will continue to create and provide solutions that can contribute to achieving a sustainable society by capitalizing on a wide array of technologies that it has cultivated as a diversified chemical company operating in its extensive areas of business.

Read More

CHEMICAL TECHNOLOGY

Vernalis Research - a Fully Owned Subsidiary of HitGen Inc - and Hannibal Innovation Announce the Creation of Dania Therapeutics ApS

Vernalis Research, | November 01, 2021

Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Hannibal Innovation ApS (“Hannibal”) are pleased to announce the creation of Dania Therapeutics ApS (“Dania”) to discover small molecules inhibitors against new undisclosed oncology targets. Dania’s new discovery program is based on the work from Professor Kristian Helin at University of Copenhagen. Prof. Helin and Dr. Karl Agger, from his laboratory, are the scientific founders of Dania. Under the terms of the agreement, Vernalis will use its expertise in drug discovery to undertake all activities up to lead optimization and invest in Dania. Vernalis has the option to fund further discovery activities until the nomination of a preclinical candidate. The team at Hannibal will run operations for Dania throughout the initial stages of the collaboration. Mike Wood – Managing Director at Vernalis - will join the Board of Dania. Hamed Brodersen and Karin Absalonsen from Hannibal will act as CEO and Chair of the Board of directors, respectively. Kim Andersen joins as COO of Dania. “We are extremely pleased to work with Kristian Helin and Hannibal on such exciting targets. This innovative business model where Vernalis trades the usual cash and milestones payments for equity demonstrates Vernalis’ confidence in its expertise and its ability to collaborate with talented scientists and successful entrepreneurs and we have been impressed by the quality of the work from Kristian and the track record from the team at Hannibal in creating and nurturing successful biotech companies.'' Mike Wood – Managing Director at Vernalis “We are very excited about the creation of Dania, and the collaboration with Hannibal and Vernalis in starting the company,” said Kristian Helin. “We are looking forward to our continued collaboration and the development of new inhibitors to the oncology targets, identified in my lab at University of Copenhagen.” “Hannibal wants to be the go-to partner for scientists and research institutions that stand out in the industry because of the depth and quality of their scientific work. It is an honor for us to work with Kristian Helin in bringing new breakthroughs in science to underserved patients. We are also thrilled to work with Vernalis, which has an excellent track record in structure-based drug discovery, a strong management team and visionary owners. Hannibal’s business model is to establish strong partnerships with innovative approaches to business development. We look forward to shaping the industry together with Kristian and Vernalis,” said Hamed Brodersen, CEO of Hannibal. About HitGen HitGen Inc. is a biotech company headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. It became a publicly listed company in Shanghai Stock Exchange in April 2020 (ticker code 688222.SH). HitGen has established a drug discovery research platform for small molecules and nucleic acid drug centered on the design, synthesis and screening of DNA encoded chemical libraries (DELs), fragment-based drug discovery (FBDD) and structure-based drug design (SBDD) technologies. HitGen's DELs currently contains more than 1 trillion novel, diverse, drug-like small molecules and macrocyclic compounds. These compounds are members of DELs synthesized from many thousands of distinct chemical scaffolds, designed with tractable chemistry, and have yielded proven results for the discovery of small molecule leads against precedented and unprecedented classes of biological targets. Through its acquisition of Cambridge UK based Vernalis R&D Ltd before the end of 2020, a leader in FBDD/SBDD, HitGen now has a research team of over 500 scientists and offers a full set of research capabilities from recombinant protein expression and purification, structural biology, assay development, screening, DEL synthesis, nucleic acid and small molecule chemical synthesis, computational and medicinal chemistry, biochemistry and biophysics, cell biology, in vivo pharmacology, DMPK, CMC, etc., to enable drug discovery research from target gene to IND filing. About Kristian Helin Kristian Helin is the CEO and President at The Institute of Cancer Research (www.icr.ac.uk) and was formerly Director of the Biotech Research & Innovation Centre, University of Copenhagen and Chair of the Cell Biology Program at Memorial Sloan Kettering Cancer Center. About Hannibal Innovation Hannibal transitions important science and technology into growth companies and provides alternative investment opportunities for long-term investors seeking higher yields. We do it to save lives, impact societies, and make a profit.

Read More